AbbVie announces new data from Phase 3 studies of RINVOQ

AbbVie announced new data analyses from the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies that further demonstrated the long-term efficacy and safety profile of RINVOQ, or upadacitinib, among adults and adolescents 12 years and older with moderate to severe atopic dermatitis through 140 weeks. Study results will be orally presented on Wednesday, October 11, at the 32nd European Academy of Dermatology and Venereology, or EADV, Congress in Berlin. In the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies, a significantly higher proportion of patients treated with upadacitinib achieved the co-primary endpoints of improvement in skin clearance, measured by an EASI score of 75 and vIGA-AD 0/1 at week 16, compared to those who received placebo.1 Additionally, more upadacitinib-treated patients achieved the secondary endpoint of improvement in skin clearance, measured by an EASI score of 90, and an additional endpoint of itch reduction at week 16, compared to placebo-treated patients.1 The efficacy of both upadacitinib doses was consistently maintained for these important measures across all three studies through week 140.1